Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin
{"title":"同源定向修复以及 BRCA1、BRCA2 和相关蛋白在基因组完整性和癌症中的作用。","authors":"Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin","doi":"10.1146/annurev-cancerbio-030617-050502","DOIUrl":null,"url":null,"abstract":"<p><p>Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially <i>BRCA1</i> and <i>BRCA2</i>, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers. HDR is critical for the error-free repair of DNA double-strand breaks and other lesions, and HDR factors also protect stalled replication forks. As a result, loss of BRCA1 or BRCA2 poses significant risks to genome integrity, leading not only to cancer predisposition but also to sensitivity to DNA-damaging agents, affecting therapeutic approaches. Here we review recent advances in our understanding of BRCA1 and BRCA2, including how they genetically interact with other repair factors, how they protect stalled replication forks, how they affect the response to aldehydes, and how loss of their functions links to mutation signatures. Importantly, given the recent advances with poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of HDR-deficient tumors, we discuss mechanisms by which BRCA-deficient tumors acquire resistance to PARPi and other agents.</p>","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":"2 ","pages":"313-336"},"PeriodicalIF":4.7000,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193498/pdf/nihms958408.pdf","citationCount":"0","resultStr":"{\"title\":\"Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.\",\"authors\":\"Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin\",\"doi\":\"10.1146/annurev-cancerbio-030617-050502\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially <i>BRCA1</i> and <i>BRCA2</i>, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers. HDR is critical for the error-free repair of DNA double-strand breaks and other lesions, and HDR factors also protect stalled replication forks. As a result, loss of BRCA1 or BRCA2 poses significant risks to genome integrity, leading not only to cancer predisposition but also to sensitivity to DNA-damaging agents, affecting therapeutic approaches. Here we review recent advances in our understanding of BRCA1 and BRCA2, including how they genetically interact with other repair factors, how they protect stalled replication forks, how they affect the response to aldehydes, and how loss of their functions links to mutation signatures. Importantly, given the recent advances with poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of HDR-deficient tumors, we discuss mechanisms by which BRCA-deficient tumors acquire resistance to PARPi and other agents.</p>\",\"PeriodicalId\":54233,\"journal\":{\"name\":\"Annual Review of Cancer Biology-Series\",\"volume\":\"2 \",\"pages\":\"313-336\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2018-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193498/pdf/nihms958408.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual Review of Cancer Biology-Series\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-cancerbio-030617-050502\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/12/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Review of Cancer Biology-Series","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-cancerbio-030617-050502","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/12/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
促进同源定向修复(HDR)的基因,特别是 BRCA1 和 BRCA2,经常在几种癌症中出现种系突变和体细胞突变,尤其是乳腺癌和卵巢癌,还有前列腺癌和其他癌症。HDR 对于无差错修复 DNA 双链断裂和其他病变至关重要,HDR 因子还能保护停滞的复制叉。因此,BRCA1 或 BRCA2 的缺失会对基因组的完整性构成重大风险,不仅会导致癌症易感性,还会导致对 DNA 损伤因子的敏感性,从而影响治疗方法。在此,我们回顾了最近在了解 BRCA1 和 BRCA2 方面取得的进展,包括它们如何与其他修复因子发生基因相互作用、它们如何保护停滞的复制叉、它们如何影响对醛的反应,以及它们的功能缺失如何与突变特征相关联。重要的是,鉴于聚(ADP-核糖)聚合酶抑制剂(PARPi)在治疗HDR缺陷肿瘤方面的最新进展,我们将讨论BRCA缺陷肿瘤对PARPi和其他药物产生耐药性的机制。
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially BRCA1 and BRCA2, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers. HDR is critical for the error-free repair of DNA double-strand breaks and other lesions, and HDR factors also protect stalled replication forks. As a result, loss of BRCA1 or BRCA2 poses significant risks to genome integrity, leading not only to cancer predisposition but also to sensitivity to DNA-damaging agents, affecting therapeutic approaches. Here we review recent advances in our understanding of BRCA1 and BRCA2, including how they genetically interact with other repair factors, how they protect stalled replication forks, how they affect the response to aldehydes, and how loss of their functions links to mutation signatures. Importantly, given the recent advances with poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of HDR-deficient tumors, we discuss mechanisms by which BRCA-deficient tumors acquire resistance to PARPi and other agents.
期刊介绍:
The Annual Review of Cancer Biology offers comprehensive reviews on various topics within cancer research, covering pivotal and emerging areas in the field. As our understanding of cancer's fundamental mechanisms deepens and more findings transition into targeted clinical treatments, the journal is structured around three main themes: Cancer Cell Biology, Tumorigenesis and Cancer Progression, and Translational Cancer Science. The current volume of this journal has transitioned from gated to open access through Annual Reviews' Subscribe to Open program, ensuring all articles are published under a CC BY license.